

Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice

Jung-Eun Park ¹ and HYUN-JIN SHIN²

¹Chungnam National University

²CHUNGNAM NATIONAL UNIVERSITY

August 17, 2020

Abstract

Rabies is a viral disease that causes severe neurological manifestations both in humans and mammals. Although inactivated and/or attenuated vaccines have been developed and widely used around the world, there are still concerns with regard to their safety, efficacy, and costs. As demand has grown for a new rabies vaccine, we have developed a new vesicular stomatitis viruses (VSVs) based rabies vaccine that replaces glycoproteins with rabies virus (RABV) glycoprotein (GP), or so-called VSV/RABV-GP. The generation of VSV/RABV-GP was evaluated with GP-specific antibodies and reduced transduction with GP-specific neutralizing antibodies. Mice immunized with VSV/RABV-GP produced higher levels of both IgM and IgG antibodies compared to inactivated RABV. The secretion profiles of IgG1 and IgG2a production suggested that VSV/RABV-GP induces the T helper cell type-2 immune bias. In addition, VSV/RABV-GP immunization produced a neutralizing antibody of 103.37 IU/mL. Our results confirm that VSV/RABV-GP could be a new potential vaccination platform for RABV.

1. INTRODUCTION

Rabies is a highly prevalent zoonotic disease worldwide and a global public health threat, causing 55,000 human deaths annually (*Hampson et al., 2015*). The causative agent of rabies is the neurotropic rabies virus (RABV), belonging to the genus *Lyssavirus* of the family *Rhabdoviridae* (*Madhusudana, Subha, Thankappan, & Ashwin, 2012*). The single-stranded, negative-sense RNA genome of RABV encodes five structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (GP), and RNA-dependent RNA polymerase (L) (*Albertini, Ruigrok, & Blondel, 2011*). GP represents the primary antigen of RABV and is the target for binding virus-neutralizing antibodies (*Albertini et al., 2011; Zhu & Guo, 2016*). Protection against rabies correlates with the presence of virus-neutralizing antibodies. According to WHO guidelines, neutralizing antibody titers higher than a serum concentration of 0.5 IU per mL are acceptable levels for protection (*Moore & Hanlon, 2010*).

Controlling rabies in animals and mass vaccination on wildlife, especially dogs and cats, have been considered the most efficient strategies for protection and spread. To this end, various rabies vaccines have been developed and commercialized over the last few years (*Ertl, 2019; Nandi & Kumar, 2010*). However, there is still a need to improve all key characteristics, such as both the safety and efficiency targeting inhibition of transmission between animals. More importantly, other essential features would include the induction of long-lasting immunity after a single administration, efficacy after oral application, innocuousness in all RABV-susceptible animals, stability and convenient handling of the vaccine, and low costs (*Amann et al., 2013*).

Vesicular stomatitis virus (VSV), a member of the family *Rhabdoviridae*, has been developed as the viral vector system for expression and especially as the vaccine platform. It has already proven to be a promising attenuated vaccine vector from many studies. Animals immunized with recombinant VSV-based vaccine

candidates are efficiently protected from variety of pathogens, such as Ebola virus, Lassa virus, Henipavirus, and severe fevers caused by the thrombocytopenia virus (*DeBuysscher, Scott, Marzi, Prescott, & Feldmann, 2014; Dong et al., 2019; Marzi, Feldmann, Geisbert, Feldmann, & Safronetz, 2015*). The biggest advantage of the VSV vector system is that it is capable of growing to substantially high titers in several cell lines *in vitro* and elicits strong humoral and cellular responses *in vivo* (*Zinkernagel, Adler, & Holland, 1978*).

Here, we developed a replication-deficient VSV-expressing RABV-GP as a potential rabies vaccine. We proved that a VSV-expressing RABV-GP elicited strong immune responses, similar to those of inactivated vaccines. Our study leverages the VSV platform to identify a promising candidate for the development of a safe and efficient rabies vaccine, which focuses on the unique features of this platform for the development of vaccine vectors against other virulent viruses.

2. MATERIALS AND METHODS

2.1 Cells and plasmids

HEK293T cells and BHK21 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 100 mM sodium pyruvate, 0.1 mM nonessential amino acids, 100 U/mL penicillin G, and 100 µg/mL streptomycin. Cell culture materials and reagents were obtained from SPL Life Sciences Co., Ltd. (Gyeonggi-do, Korea) and Gibco® BioSciences (Dublin, Ireland) unless otherwise noted.

The codon-optimized RABV-GP gene of strain Era (GenBank accession no. EF206707) was synthesized from GenScript® and cloned into the pcDNA3.1 vector. Plasmids encoding VSV-G Indiana and pHEF-VSV-G were provided by BEI Resources (Manassas, VA, USA).

2.2 VSV pseudotyped virus preparation and transduction

HEK293T cells were transfected with either the pcDNA3.1-RABV-GP, pHEF-VSV-G, or pcDNA3.1 empty vector. For transfection, plasmid DNAs were incubated with polyethyleneimine (PEI; Polysciences, Inc., Warrington, PA, USA) at 1:3 DNA:PEI ratios in Opti-MEM (Life Technologies, Carlsbad, CA, USA) for 15 min at room temperature, and then added dropwise to the adherent cells (2 µg DNA per 10⁶ cells). At 24 h post-transfection, cells transduced with VSVluc-VSV[?]G were complemented with Junin virus glycoproteins for 1 h. Cell-free supernatants were collected at 24-72 h post-transduction and filtered through a 0.45 µm filter. The pseudotyped viruses in the supernatants were pelleted by centrifugation at 10,000 × g for 10-18 h, suspended in phosphate-buffered saline (PBS, pH 7.4), and kept at -80 degC until use.

For transduction, BHK21 cells were incubated with pseudotyped viruses at normalized inputs, based on VSV M protein levels, for 1 h at 37 degC. Where indicated, mouse anti-C9 (Santa Cruz) or monoclonal mouse anti-rabies virus (Rab-50, Santa Cruz) were added during virus absorption. At 18 h post-transduction, cells were lysed, and luciferase levels were quantified as a measure of VSV pseudotyped virus entry.

2.3 Mouse immunization and sample collection

Eight-week-old BALB/c mice were randomized into three groups. All groups were vaccinated intraperitoneally twice at 2 week intervals. Mice in group 1 were given PBS and 50 µL Alum adjuvant as controls. Mice in group 2 were given 10 µg of VSV/RABV-GP and 50 µL Alum adjuvant. Mice in group 3 were given 10 µg of inactivated RABV and 50 µL Alum adjuvant. At 28 post-initial immunizations, serum samples were collected.

2.4 Enzyme-linked immunosorbent assay (ELISA)

For sandwich ELISA, 96-well microplates were coated with mouse monoclonal anti-rabies virus (RV1C5, Santa Cruz) at 1 µg/ml concentration in carbonate/bicarbonate buffer (pH 9.6) and incubated overnight at 4 °C. The plates were blocked with 5% non-fat dry milk in PBS at room temperature (RT) for 2 h and

then with serially diluted VSV/RABA-GP at RT for 2 h. After four washes with PBS-T, the plates were incubated with horseradish peroxidase (HRP) conjugated anti-rabies virus (Rab-50) at RT for 1 h.

For indirect ELISA, ELISA plates were coated with inactivated RABV in carbonate/bicarbonate buffer (pH 9.6) overnight at 4 °C. The plates were blocked with 5% non-fat dry milk in PBS at RT for 2 h and then with serially diluted mouse sera at RT for 2 h. After four washes with PBS-T, the plates were incubated with HRP conjugated anti-mouse IgG, IgM, IgG1 or IgG2a at RT for 1 h. The reaction was visualized by substrate 3,3',5,5'-tetramethylbenzidine and stopped with 1N H₂SO₄. The absorbance at 450 nm was measured by ELISA plate reader.

2.5 Virus neutralization assays

FAVNT (fluorescent antibody virus neutralization test) was performed as previously described (*Smith, Yager, & Baer, 1973*). The serum neutralizing titers were converted and presented in international units per milliliter (IU/mL).

2.6 Statistical analyses

All experiments were independently repeated at least three times. Data are presented as mean \pm SD. Statistical significance was calculated using the Holm-Sidak multiple Student's *t*-test. A P value of < 0.05 was considered statistically significant.

RESULTS

3.1 Generation and characterization of VSV/RABV-GP

To generate VSV/RABV-GP, the GP gene of RABV from the Era strain was cloned into the pcDNA3.1 vector and is designated as pcDNA3.1-RABV-GP. The VSV/RABV-GP pseudo-typed virus was generated in HEK293T cells, as described previously (*Park et al., 2016*). The incorporation of RABV-GP was verified by sandwich ELISA. As shown in Figure 1A, the absorbance at 450nm in wells containing VSV/RABV-GP was significantly higher than that in wells containing VSV/VSV-GP or background. To evaluate whether the recombinant GP was antigenically similar to wild type RABV-GP, the response to neutralizing antibodies in BHK21 cells was evaluated. As shown in Figure 1B, VSV/RABV-GP transduction was significantly reduced by neutralizing antibodies, but it was not affected by the off-target antibody (anti-C9), which was used as a control. As expected, no inhibitory activity was detected against VSV/VSV-GP, the negative control. These results clearly confirmed that the RABV-GP was incorporated correctly on the surface of the VSV pseudotyped virus and displayed critical neutralizing epitopes such that it induced potential neutralizing antibodies against RABV.

3.2 Humoral immune responses induced by VSV/RABV-GP vaccination

Next, we evaluated the immunogenicity of VSV/RABV-GP in mice. Eight-week-old BALB/C mice were intraperitoneally immunized either with VSV/RABV-GP or inactivated RABV (Figure 2A). None of the inoculated mice demonstrated any clinical signs or weight loss (data not shown), suggesting that VSV/RABA-GP immunization was safe as an inactivated control. On day 28 of post-immunization, IgM and IgG titers were examined. The IgM titers in mice immunized with VSV/RABV-GP were significantly three times higher than those in mice immunized with inactivated RABV (OD value 1.2 and 3.8, respectively), as shown in Figure 2B. Even in the variation of IgM titer in each mouse, a higher variation was found in the RABV vaccine group, but very low variation was found in the VSV/RABV-GP group (Figure 2B). Comparing IgG titers, both groups showed a strong IgG titer (OD value of 2.9); however, there were no statistical differences between the two groups (Figure 2C). We confirmed that VSV/RABV-GP vaccination induced the same level of IgG with inactivated RABV. Based on these humoral response results, we confirmed that VSV/RABV-GP induced strong antibodies of both IgG and IgM. Moreover, it induced at least the same or a higher antibody titer than inactivated RABV.

3.3 VSV/RABV-GP induces a T helper cell type-2 (Th2) immune bias

To determine whether Th1 and/or Th2 humoral response was induced by vaccination with VSV/RABV-GP, the levels of specific IgG1 and IgG2a subclasses were compared with the inactivated RABV vaccine. Sera samples showed statistically indistinguishable GP-specific IgG1 and IgG2a responses (Figure 3A and B). Analysis of the antigen-specific IgG1/IgG2a ratio in the sera samples revealed that mice immunized with VSV/RABV-GP had a greater IgG1/IgG2a than the inactivated RABV (Figure 3C). The data indicate that VSV/RABA-GP induces a Th2-biased immune response.

3.4 Protective efficacy of VSV/RABV-GP vaccination

To determine the protective efficacy of VSV/RABV-GP vaccination, the neutralizing activity of the sera samples was analyzed by FAVNT. The average serum neutralization titers of the inactivated RABV and VSV/RABV-GP groups were 241.41 and 103.37 IU/mL, respectively (Figure 4).

DISCUSSION

Rabies was, after smallpox, the second human disease for which an efficacious vaccine was developed, by Pasteur in 1885. Although it is eminently preventable, with highly efficacious vaccines available for both humans and animals, it still causes considerable mortality in low and middle-income countries (*Hampson et al., 2015*). Primary prevention is the best defense against rabies. It includes the following: elimination of animal rabies through dog vaccination campaigns; promoting awareness of the disease and available prevention; and encouraging responsible dog ownership and vaccination, particularly in endemic areas, where existing cultural practices might need to be adapted to integrate these interventions (*Banyard, Horton, Freuling, Muller, & Fooks, 2013*). Where possible, rabies pre-exposure prophylaxis (PrEP) via immunization is recommended for travelers to endemic regions, although such advice might not always be followed (*Fooks, Johnson, Brookes, Parsons, & McElhinney, 2003*). However, in the absence of infrastructure to support such initiatives, secondary prevention attempts to prevent the onset of clinical disease through post-exposure prophylaxis (PEP). Most human cases of rabies are the result of dog bites (*Fooks et al., 2017*). There is a strong argument for investment in dog vaccination: the feasibility and cost-effectiveness of rabies control and human rabies elimination by dog vaccination has been demonstrated in some countries (*Wang, C. et al., 2018*). Several inactivated preparations of RABV are available as vaccines to immunize humans and domestic animals. For wildlife vaccination, both live-attenuated and subunit vaccines are available (*Rupprecht, Nagarajan, & Ertl, 2016*). Licensed human rabies vaccines are all based upon an inactivated rabies virus and may be used either for PrEP as well as PEP (*Chulasugandha, Khawplod, Havanond, & Wilde, 2006*). PrEP regimes have until recently involved three doses of inactivated rabies virus vaccine spread over 28 days with typical costs (*Chulasugandha et al., 2006*). Not only inactivated vaccines, but also other recombinant vaccines trials are reported elsewhere. Recently, a simian adenovirus-vectored candidate showed that single-dose vaccination induced strong neutralizing antibodies in mice (*Wang, C. et al., 2018*). Also, other rabies vaccine candidates using viral vectors have been reported (*Abreu-Mota et al., 2018; Chen et al., 2019; Ramya et al., 2011; Wang, X. et al., 2019*). Very recently, RNA vaccines for rabies were reported (*Armbruster, Jasny, & Petsch, 2019*).

The importance of rabies immunoglobulin (RIG) has been studied. PEP can include both the administration of RIG and vaccination, although individuals who receive adequate PrEP should receive a booster vaccination but not RIG. The application of RIG directly to the wound aims to neutralize any live virus in the immediate wound area and prevent the spread of the virus in the time that it takes to develop sufficient immunity in response to vaccination.

In the present study, we generated VSV/RABV-GP and investigated its immunogenicity in mice. The results described above demonstrate that the VSV/RABV-GP immunization can elicit a strong, specific humoral immune response in mice. The average neutralizing titer in immunized mice was 103 IU/ml, which is higher than the recommended lowest titers by the WHO. VSV/RABV-GP did not induce cytotoxic effects in transduced cells or the immunized mice. Collectively, the data suggest that VSV/RABV-GP is a promising candidate for rabies vaccine.

Vaccination is considered the best way to combat a rabies infection before and after exposure, as there is

no treatment available once the symptoms have appeared. Since the nerve tissue vaccine was first developed by Pasteur in 1885, various rabies vaccines for animal and human use have been developed (Ertl, 2019; Nandi & Kumar, 2010). Inactivated nerve tissue vaccines are economically beneficial but can cause serious side effects, such as autoimmune encephalomyelitis in inoculated animals (Cliquet & Picard-Meyer, 2004). Inactivated cell cultures and embryonated egg vaccines have replaced nerve tissue vaccines and are considered safe and are well-tolerated (Kamoltham, Khawplod, & Wilde, 2002; Kamoltham et al., 2007). However, these vaccines are expensive and unaffordable for people and animals living in developing countries. Attenuated live vaccines can efficiently elicit a protective immune response without the use of adjuvants. In contrast, there is a potential risk for rabies in the inoculated animals due to their residual virulence or pathogenic mutation during viral propagation (Nandi & Kumar, 2010).

The replication-deficient VSV-vector vaccine is a promising vaccine platform that is safe and effective. Single-cycle VSV-based vectors lacking the VSV G protein can infect cells but cannot produce infectious particles (Schnell, Johnson, Buonocore, & Rose, 1997). Therefore, there are no potential safety issues associated with infectious vaccines. In addition, VSV proteins have adjuvant-like properties, thereby eliciting robust adaptive immune responses to the vaccine immunogen (Cobleigh, Bradfield, Liu, Mehta, & Robek, 2012; Tober et al., 2014; Wu, Fan, Yue, Xiong, & Dong, 2014). Nevertheless, although the VSV protein(s) is important for this enhancing effect, it has not been fully identified.

IgM possesses multiple functions that promote effective antimicrobial properties, including particle agglutination (direct neutralization), complement activation, and enhanced phagocytosis. In addition, IgM has the ability to influence the generation of adaptive immunity (Boes et al., 1998) and to influence the magnitude of virus-specific IgG antibody responses (Baumgarth et al., 2000). Natural IgM is present in the blood at high concentrations, while immune IgM is the first antibody isotype induced upon infection or immunization, suggesting that vaccine-induced IgM may help to improve the efficacy of RABV vaccination in the context of PEP (Racine & Winslow, 2009). IgM plays critical roles in limiting virus dissemination for some neurotropic and non-neurotropic viruses, including West Nile virus (Diamond et al., 2003), influenza virus (Baumgarth et al., 2000; Kopf, Brombacher, & Bachmann, 2002), and vesicular stomatitis virus (Hangartner, Zinkernagel, & Hangartner, 2006). The role of IgM generated from RABV vaccination and its protection have been studied elsewhere. Dorfmeier et al. reported that antibody subtype and subclass revealed the potential for early protective IgM antibodies in recombinant RABV-M-immunized mice (Dorfmeier, Lytle, Dunkel, Gatt, & McGettigan, 2012). One IgM antibody is needed to cover 9 or 10 glycoprotein spikes on the surface of RABV particles for neutralization, compared to one or two IgG antibodies to cover only three glycoprotein spikes (Flamand, Raux, Gaudin, & Ruigrok, 1993). Very recently, Dorfmeier et al. reported that IgM showed a very important role in postexposure vaccination (Dorfmeier, Shen, Tzvetkov, & McGettigan, 2013). Taken together, the information from all reference studies suggests that immune IgM is induced in response to vaccination, and that the high valency and lower number of IgM than IgG needed to cover the RABV spike glycoproteins make induced IgM attractive from a PEP vaccination standpoint.

In conclusion, replication-deficient VSVs expressing RABV-GP displayed well-folded RABV-GP on their surface and elicited potent humoral immune responses. To our knowledge, no VSV-based vaccines against RABV have been reported. Our study provides a novel and efficient strategy for developing vaccines against this specific viral infection. However, the significant differences between mice, dogs, and humans should not be overlooked. Therefore, confirming the effectiveness and safety of vaccines in humans and dogs is an important topic for future research on vaccines against rabies. In particular, based on high level of IgM induced, our vaccine might be useful for postexposure vaccination.

ACKNOWLEDGEMENTS

This work was supported by Basic Science Research Program Through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A3B03033883) and research fund of Chungnam National University.

CONFLIT OF INTEREST

The authors declare that they have no conflict of interest.

ETHICAL STATEMENT

All the animal experiments were performed according to the protocol approved by the Institutional Animal Care and Use Committee of Chungnam National University (ethics approval number: CNU-01184).

DATA AVAILABILITY STATEMENT

The same data that support the findings of this study are available on request from the corresponding author.

REFERENCES

- Abreu-Mota, T., Hagen, K. R., Cooper, K., Jahrling, P. B., Tan, G., Wirblich, C., . . . Schnell, M. J. (2018). Non-neutralizing antibodies elicited by recombinant lassa-rabies vaccine are critical for protection against lassa fever. *Nature Communications*, 9 (1), 4223-018-06741-w. doi:10.1038/s41467-018-06741-w [doi]
- Albertini, A. A., Ruigrok, R. W., & Blondel, D. (2011). Rabies virus transcription and replication. *Advances in Virus Research*, 79 , 1-22. doi:10.1016/B978-0-12-387040-7.00001-9 [doi]
- Amann, R., Rohde, J., Wulle, U., Conlee, D., Raue, R., Martinon, O., & Rziha, H. J. (2013). A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. *Journal of Virology*, 87 (3), 1618-1630. doi:10.1128/JVI.02470-12 [doi]
- Armbruster, N., Jasny, E., & Petsch, B. (2019). Advances in RNA vaccines for preventive indications: A case study of A vaccine against rabies. *Vaccines*, 7 (4), 10.3390/vaccines7040132. doi:E132 [pii]
- Banyard, A. C., Horton, D. L., Freuling, C., Muller, T., & Fooks, A. R. (2013). Control and prevention of canine rabies: The need for building laboratory-based surveillance capacity. *Antiviral Research*, 98 (3), 357-364. doi:10.1016/j.antiviral.2013.04.004 [doi]
- Baumgarth, N., Herman, O. C., Jager, G. C., Brown, L. E., Herzenberg, L. A., & Chen, J. (2000). B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. *The Journal of Experimental Medicine*, 192 (2), 271-280. doi:10.1084/jem.192.2.271 [doi]
- Boes, M., Esau, C., Fischer, M. B., Schmidt, T., Carroll, M., & Chen, J. (1998). Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. *Journal of Immunology (Baltimore, Md.: 1950)*, 160 (10), 4776-4787.
- Chen, T., Zhou, X., Qi, Y., Mi, L., Sun, X., Zhang, S., . . . Hu, R. (2019). Feline herpesvirus vectored-rabies vaccine in cats: A dual protection. *Vaccine*, 37 (16), 2224-2231. doi:S0264-410X(19)30310-X [pii]
- Chulasugandha, P., Khawplod, P., Havanond, P., & Wilde, H. (2006). Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in thai children. *Vaccine*, 24 (9), 1478-1482. doi:S0264-410X(05)00993-X [pii]
- Cliquet, F., & Picard-Meyer, E. (2004). Rabies and rabies-related viruses: A modern perspective on an ancient disease. *Revue Scientifique Et Technique (International Office of Epizootics)*, 23 (2), 625-642. doi:10.20506/rst.23.2.1514 [doi]
- Cobleigh, M. A., Bradfield, C., Liu, Y., Mehta, A., & Robek, M. D. (2012). The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. *Journal of Virology*, 86 (8), 4253-4261. doi:10.1128/JVI.05991-11 [doi]
- DeBuysscher, B. L., Scott, D., Marzi, A., Prescott, J., & Feldmann, H. (2014). Single-dose live-attenuated nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. *Vaccine*, 32 (22), 2637-2644. doi:10.1016/j.vaccine.2014.02.087 [doi]

- Diamond, M. S., Sitati, E. M., Friend, L. D., Higgs, S., Shrestha, B., & Engle, M. (2003). A critical role for induced IgM in the protection against west nile virus infection. *The Journal of Experimental Medicine*, 198 (12), 1853-1862. doi:10.1084/jem.20031223 [doi]
- Dong, F., Li, D., Wen, D., Li, S., Zhao, C., Qi, Y., . . . Zheng, A. (2019). Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. *NPJ Vaccines*, 4 , 5-018-0096-y. eCollection 2019. doi:10.1038/s41541-018-0096-y [doi]
- Dorfmeier, C. L., Lytle, A. G., Dunkel, A. L., Gatt, A., & McGettigan, J. P. (2012). Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection. *Journal of Virology*, 86 (21), 11533-11540. doi:10.1128/JVI.00615-12 [doi]
- Dorfmeier, C. L., Shen, S., Tzvetkov, E. P., & McGettigan, J. P. (2013). Reinvestigating the role of IgM in rabies virus postexposure vaccination. *Journal of Virology*, 87 (16), 9217-9222. doi:10.1128/JVI.00995-13 [doi]
- Ertl, H. C. J. (2019). New rabies vaccines for use in humans. *Vaccines*, 7 (2), 10.3390/vaccines7020054. doi:E54 [pii]
- Flamand, A., Raux, H., Gaudin, Y., & Ruigrok, R. W. (1993). Mechanisms of rabies virus neutralization. *Virology*, 194 (1), 302-313. doi:S0042-6822(83)71261-4 [pii]
- Fooks, A. R., Cliquet, F., Finke, S., Freuling, C., Hemachudha, T., Mani, R. S., . . . Banyard, A. C. (2017). Rabies. *Nature Reviews.Disease Primers*, 3 , 17091. doi:10.1038/nrdp.2017.91 [doi]
- Fooks, A. R., Johnson, N., Brookes, S. M., Parsons, G., & McElhinney, L. M. (2003). Risk factors associated with travel to rabies endemic countries. *Journal of Applied Microbiology*, 94 Suppl , 31S-36S. doi:1883 [pii]
- Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., . . . Global Alliance for Rabies Control Partners for Rabies Prevention. (2015). Estimating the global burden of endemic canine rabies. *PLoS Neglected Tropical Diseases*, 9 (4), e0003709. doi:10.1371/journal.pntd.0003709 [doi]
- Hangartner, L., Zinkernagel, R. M., & Hangartner, H. (2006). Antiviral antibody responses: The two extremes of a wide spectrum. *Nature Reviews.Immunology*, 6 (3), 231-243. doi:nri1783 [pii]
- Kamoltham, T., Khawplod, P., & Wilde, H. (2002). Rabies intradermal post-exposure vaccination of humans using reconstituted and stored vaccine. *Vaccine*, 20 (27-28), 3272-3276. doi:S0264410X02002992 [pii]
- Kamoltham, T., Thinyoung, W., Phongchamnaphai, P., Phraisuwan, P., Khawplod, P., Banzhoff, A., & Malerczyk, C. (2007). Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. *The Journal of Pediatrics*, 151 (2), 173-177. doi:S0022-3476(07)00170-9 [pii]
- Kopf, M., Brombacher, F., & Bachmann, M. F. (2002). Role of IgM antibodies versus B cells in influenza virus-specific immunity. *European Journal of Immunology*, 32 (8), 2229-2236. doi:10.1002/1521-4141(200208)32:83.0.CO;2-T [doi]
- Madhusudana, S. N., Subha, S., Thankappan, U., & Ashwin, Y. B. (2012). Evaluation of a direct rapid immunohistochemical test (dRIT) for rapid diagnosis of rabies in animals and humans. *Virologica Sinica*, 27 (5), 299-302. doi:10.1007/s12250-012-3265-6 [doi]
- Marzi, A., Feldmann, F., Geisbert, T. W., Feldmann, H., & Safronetz, D. (2015). Vesicular stomatitis virus-based vaccines against lassa and ebola viruses. *Emerging Infectious Diseases*, 21 (2), 305-307. doi:10.3201/eid2102.141649 [doi]
- Moore, S. M., & Hanlon, C. A. (2010). Rabies-specific antibodies: Measuring surrogates of protection against a fatal disease. *PLoS Neglected Tropical Diseases*, 4 (3), e595. doi:10.1371/journal.pntd.0000595 [doi]

- Nandi, S., & Kumar, M. (2010). Development in immunoprophylaxis against rabies for animals and humans. *Avicenna Journal of Medical Biotechnology*, 2 (1), 3-21.
- Park, J. E., Li, K., Barlan, A., Fehr, A. R., Perlman, S., McCray, P. B., Jr, & Gallagher, T. (2016). Proteolytic processing of middle east respiratory syndrome coronavirus spikes expands virus tropism. *Proceedings of the National Academy of Sciences of the United States of America*, 113 (43), 12262-12267. doi:1608147113 [pii]
- Racine, R., & Winslow, G. M. (2009). IgM in microbial infections: Taken for granted? *Immunology Letters*, 125 (2), 79-85. doi:10.1016/j.imlet.2009.06.003 [doi]
- Ramya, R., Mohana Subramanian, B., Sivakumar, V., Senthilkumar, R. L., Sambasiva Rao, K. R., & Srinivasan, V. A. (2011). Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice. *Clinical and Vaccine Immunology : CVI*, 18 (10), 1673-1679. doi:10.1128/CVI.05258-11 [doi]
- Rupprecht, C. E., Nagarajan, T., & Ertl, H. (2016). Current status and development of vaccines and other biologics for human rabies prevention. *Expert Review of Vaccines*, 15 (6), 731-749. doi:10.1586/14760584.2016.1140040 [doi]
- Schnell, M. J., Johnson, J. E., Buonocore, L., & Rose, J. K. (1997). Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. *Cell*, 90 (5), 849-857. doi:S0092-8674(00)80350-5 [pii]
- Smith, J. S., Yager, P. A., & Baer, G. M. (1973). A rapid reproducible test for determining rabies neutralizing antibody. *Bulletin of the World Health Organization*, 48 (5), 535-541.
- Tober, R., Banki, Z., Egerer, L., Muik, A., Behmuller, S., Kreppel, F., . . . Kimpel, J. (2014). VSV-GP: A potent viral vaccine vector that boosts the immune response upon repeated applications. *Journal of Virology*, 88 (9), 4897-4907. doi:10.1128/JVI.03276-13 [doi]
- Wang, C., Dulal, P., Zhou, X., Xiang, Z., Goharriz, H., Banyard, A., . . . Douglas, A. D. (2018). A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. *PLoS Neglected Tropical Diseases*, 12 (10), e0006870. doi:10.1371/journal.pntd.0006870 [doi]
- Wang, X., Fang, Z., Xiong, J., Yang, K., Chi, Y., Tang, X., . . . Zhou, D. (2019). A chimpanzee adenoviral vector-based rabies vaccine protects beagle dogs from lethal rabies virus challenge. *Virology*, 536 , 32-38. doi:S0042-6822(19)30198-9 [pii]
- Wu, F., Fan, X., Yue, Y., Xiong, S., & Dong, C. (2014). A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. *Vaccine*, 32 (31), 3917-3926. doi:10.1016/j.vaccine.2014.05.052 [doi]
- Zhu, S., & Guo, C. (2016). Rabies control and treatment: From prophylaxis to strategies with curative potential. *Viruses*, 8 (11), 10.3390/v8110279. doi:E279 [pii]
- Zinkernagel, R. M., Adler, B., & Holland, J. J. (1978). Cell-mediated immunity to vesicular stomatitis virus infections in mice. *Experimental Cell Biology*, 46 (1-2), 53-70. doi:10.1159/000162882 [doi]

Figure legends

FIGURE 1. Generation and characterization of VSV/RABV-GP. (A) VSV/RABV-GP production was measured by sandwich ELISA. Results have been expressed as the mean of OD450 \pm SD values and are representative of at least three independent experiments. Dotted line indicates the background. (B) BHK21 cells were transduced with VSV/RABV-GP or VSV/VSV-GP in the presence or absence of the indicated antibodies. Virus entry was quantified by measuring the luciferase levels at 18 h post-transduction. Error bars represent the SD from the mean (n = 3). Statistical significance was assessed by Student's *t*-test. *, P<0.05, ***, P<0.001; ns, not significant.

FIGURE 2. Immunization schedule and humoral immune response induced by vaccination. (A) Schematic diagram of the immunization protocol. BALB/c mice were i.p. immunized with PBS, RABA, or VSV/RABV-GP at 0 and 14 days after the first immunization. At 28 days post immunization, mice were sacrificed and serum samples were collected. (B and C) Detection of the levels of RABV GP specific IgM (B) and IgG (C). Results are expressed as the mean ($n=3$) of $OD_{450} \pm SD$ values and are representative of at least three independent experiments. Statistical significance was assessed by Student's t -test. ***, $P<0.001$; ns, not significant.

FIGURE 3. Influence of VSV/RABV-GP immunization on the type of T helper cell response. The serum specific IgG1 (A) and IgG2a (B) titers were determined as indicators of a Th1 or Th2 type of response, respectively. (C) IgG1/IgG2a titer ratios of immunized mice. Results are expressed as the mean ($n=3$) of $OD_{450} \pm SD$ values and are representative of at least three independent experiments. Statistical significance was assessed by Student's t -test. ns, not significant.

FIGURE 4. Protective efficacy of VSV/RABV-GP vaccination. Detection of neutralizing antibody titers in the serum of the immunized mice by fluorescent antibody virus neutralization test (FAVNT). Results are expressed as the mean ($n=3$) of serum neutralizing titers $\pm SD$ values and are representative of at least three independent experiments. Statistical significance was assessed by Student's t -test. *, $P<0.05$.

Hosted file

VSV-RV figure_20200531.pptx available at <https://authorea.com/users/351123/articles/475784-immunogenicity-of-replication-deficient-vesicular-stomatitis-virus-based-rabies-vaccine-in-mice>